A retrospective cohort study that included 228 patients with advanced NSCLC and 73 with early stage disease revealed that those under therapeutics with ACE inhibitors (iACE) or AT1 receptor blockers, in combination with standard chemotherapy or tyrosine kinase inhibitors, had a positive effect on progression-free survival and overall survival, regardless of lung cancer stage [65]. The gene discussed is AGTR1; the disease is lung carcinoma.